United Kingdom: Implications of Brexit for IP rights

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

United Kingdom: Implications of Brexit for IP rights

On March 29, Prime Minister Theresa May triggered Article 50, formally notifying the European Union of the UK's intention to withdraw from the EU. The UK government now begins the lengthy process of negotiating the terms of our exit with our European partners.

Initially, there will be no change as the UK will remain an EU member until the process has been completed, which is estimated to be at least two years, possibly considerably longer.

Brexit will have no effect on the usual system for European patents. In terms of IP it is important to differentiate the terms EU and Europe. European patents cover territories which are different to the member states of the EU. The UK will continue to be a member of the European Patent Organisation which is a separate body from the EU. UK patent protection will continue to be available via the European Patent Office and UK-based qualified European patent attorneys will act in the usual way in all matters before the EPO.

In the case of European Union trade marks (EUTMs) and registered Community designs (RCDs), nothing will change until the leaving process is complete, so the impact of Brexit will depend on the outcome of the negotiations. Until that point, EUTMs and RCDs remain in force and cover the UK. We fully expect that EUTM holders will not lose their UK rights, and are monitoring this situation. Organisations should review their EUTM portfolio to identify those trade marks of most value to their UK business and consider re-filing in the UK if they identify that the present EU/UK negotiated outcome may present a risk to their trade mark rights. National UK IP rights, including trade marks and designs, will, of course, be unaffected by Brexit.

Also, IP agreements with other parties should be checked for any potential implications in light of the UK exit.

The UK is to remain part of the Unitary Patent and Unified Patent Court system. The UK Intellectual Property Office has confirmed that the government's preparations for ratification of the UPC Agreement are "fully on track" to allow the UK-based UPC to open in December 2017 as per the preparatory committee's timetable.

Chapman

Helga Chapman

Chapman + Co

Patent and Trade Mark Attorneys

Chapman IP, Kings Park House, 22 Kings Park Road

Southampton SO15 2AT, UK

Tel: +44 (0) 23 8000 2022 

info@chapmanip.com  

www.chapmanip.com

more from across site and SHARED ros bottom lb

More from across our site

The US decision marks a rare grant of a request under the Uniform Fraudulent Transfer Act in a patent case
Stobbs has applied to strike out a contempt of court application filed against the firm and two of its lawyers
With trademark volumes surging, trademark teams need to think beyond traditional clearance searches, towards a continuous, intelligence-led workflow, says Meghan Medeiros of Corsearch
Brazilian in-house counsel say law firms’ technology investments have not translated into tangible benefits, meaning tech use is a minor factor when selecting advisers
A lack of comfort among some salaried partners shows why law firms must actively foster inclusion, not merely focus on diversity mandates
Arrival of Laura Alonso, alongside a team of 11, will bring ‘significant value’ to ECIJA clients, says CEO
In the first of a two-part article, lawyers at Spruson & Ferguson and Marshall Gerstein provide an overview of China’s system for appealing against patent invalidation decisions
Lawyers and corporate leaders at INTA’s Business of M&A conference in New York discussed how cross-practice collaboration and early in-house involvement can help deals
Lily Li, partner at Morrison Foerster, shares how her litigation team helped secure victory at the ITC in a patent infringement case
Top talking points also included news of an appellate ruling concerning ‘Pisco’ and Indian drugmakers gearing up to launch generic versions of Ozempic as Novo Nordisk’s patent expires
Gift this article